Allotera Therapeutics (formerly Wugen) is a pivotal-stage biotechnology company developing allogeneic, off-the-shelf CAR-T cell therapies for cancer.  The company is advancing Soficabtagene Geleucel, or Sofi-cel, its lead CD7-targeted CAR-T cell therapy, through a global pivotal study for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.  Allotera’s gene-editing and manuacturing approach is intended to address key biological and practical barriers that have limited CAR-T therapy development in T-cell cancers.  RiverVest co-founded the company based on technology licensed from Washington University in St. Louis.